What is Aprea Therapeutics Price-to-Operating-Cash-Flow?
As of today (2024-04-28), Aprea Therapeutics's share price is $5.20.
Aprea Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.38. Hence, Aprea Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for Aprea Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:
Aprea Therapeutics's Cash Flow from Operations per share for the
three
months ended in Dec. 2023 was $-1.00.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.38.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 56.00% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 34.40% per year.
During the past 7 years, Aprea Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 56.00% per year. The lowest was -25.70% per year. And the median was 13.45% per year.
Aprea Therapeutics Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Aprea Therapeutics's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aprea Therapeutics Price-to-Operating-Cash-Flow Chart
|
Aprea Therapeutics Annual Data
|
|
Trend |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
- |
- |
- |
- |
- |
|
Aprea Therapeutics Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of Aprea Therapeutics's Price-to-Operating-Cash-Flow
For the Biotechnology subindustry, Aprea Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aprea Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aprea Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Aprea Therapeutics's Price-to-Operating-Cash-Flow falls into.
Aprea Therapeutics Price-to-Operating-Cash-Flow Calculation
Aprea Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 5.20 | / | -3.377 |
| = | |
Aprea Therapeutics's Share Price of today is $5.20.
Aprea Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.38.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Aprea Therapeutics (Aprea Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
3805 Old Easton Road, Doylestown, PA, USA, 18902
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).
Executives
| Jean-pierre Bizzari |
director |
235 LAUREL LN, HAVERFOLD PA 19041 |
| Bernd R. Seizinger |
director |
535 BOYLSTON STREET, BOSTON MA 02116 |
| Gabriela Gruia |
director |
C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451 |
| John P. Hamill |
officer: SrVP/CFO/Prin. Fin &Acctg. Off |
4092 NEW HOPE ROAD, FURLONG PA 18925 |
| Michael Grissinger |
director |
C/O RESTORBIO, INC., 500 BOYLSTON ST., 12TH FLOOR, BOSTON MA 02116 |
| Marc Duey |
director |
27 STRATHMORE ROAD, NATICK MA 01760 |
| Oren Gilad |
officer: President, CEO |
535 BOYLSTON STREET, BOSTON MA 02116 |
| Rifat Pamukcu |
director |
535 BOYLSTON STREET, BOSTON MA 02116 |
| Christian S Schade |
director, officer: President & CEO |
MEDAREX, 707 STATE ROAD, PRINCETON NJ 08540 |
| Eyal C. Attar |
officer: SVP, Chief Medical Officer |
535 BOYLSTON STREET, BOSTON MA 02116 |
| Gregory Alan Korbel |
officer: Chief Business Officer |
535 BOYLSTON STREET, BOSTON MA 02116 |
| Lars B. Abrahmsen |
officer: SVP, Chief Scientific Officer |
535 BOYLSTON STREET, BOSTON MA 02116 |
| Jeremy Green |
10 percent owner |
45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001 |
| Redmile Group, Llc |
10 percent owner |
ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129 |
| 5am Ventures Iv, L.p. |
10 percent owner |
501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
Aprea Therapeutics (Aprea Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
APRE has been successfully added to your